Disease of orbital part of eye adnexa

This study tests an experimental drug called Lu AG22515 in 20 adults with moderate-to-severe thyroid eye disease, an autoimmune condition that causes eye swelling and bulging. The main goal is to see if the drug can reduce eye bulging over 24 weeks. Participants receive the drug …

This phase 3 trial tests an investigational drug called VRDN-003, given as an injection under the skin, for people with thyroid eye disease. The study involves 320 participants and aims to check the drug's safety and tolerability. Researchers will also measure if it reduces eye b…

This phase 3 trial tests an investigational drug called VRDN-003 in 204 people with chronic thyroid eye disease (TED). The drug is given as a shot under the skin and aims to reduce eye bulging and other symptoms. Participants are randomly assigned to receive either VRDN-003 or a …

This study tests a drug called satralizumab in 127 people with moderate-to-severe thyroid eye disease, a condition that causes eye bulging and discomfort. Participants receive either the drug or a placebo to see if it reduces eye bulging by at least 2 millimeters over 24 weeks. T…

This Phase 3 trial tests satralizumab, a drug that blocks IL-6, in 131 people with moderate-to-severe thyroid eye disease. The main goal is to see if it reduces eye bulging by at least 2 mm after 24 weeks. Participants receive either satralizumab or placebo injections, and resear…

This study tests a drug called TOUR006 in 79 people with active thyroid eye disease, a condition that causes eye bulging and inflammation. Participants receive either a low dose, high dose, or placebo injection every 8 weeks. The main goal is to see if the drug can reduce eye bul…

This Phase 3 trial tests an investigational drug called VRDN-003 for active thyroid eye disease, a condition that causes eye bulging, redness, and discomfort. The study involves 132 adults with moderate to severe symptoms. Participants receive either VRDN-003 or a placebo as a sh…

This phase 3 trial tests an injectable drug called teprotumumab for people with moderate-to-severe active thyroid eye disease, a condition that causes eye bulging and discomfort. About 89 adults will receive either the drug or a placebo injection to see if it reduces eye bulging …

This study tests a low-level light therapy mask for dry eye disease in people with Graves' eye disease who haven't improved with standard treatments. Thirty adults will receive either the real light therapy or a sham device. The goal is to see if the treatment improves tear film …

This research study aims to create a simple, non-invasive test using tears and blood to predict which patients with hyperthyroidism are at risk of developing Graves' Orbitopathy (eye disease). Researchers will analyze samples from 90 participants, including healthy controls and t…

This Phase 1 trial is testing a new drug called NTB003 in 40 healthy adults to see if it is safe and how the body processes it. Participants will receive either NTB003 or a placebo in increasing doses. The study is an early step toward possibly treating thyroid eye disease, but i…